Water Street Invests in Generic Injectables
Water Street Healthcare Partners, an investment firm focused on the healthcare industry, has invested in Custopharm, Inc., a generic injectable drug services company.
Founded n 2005, Custopharm specializes in generic injectable product development and regulatory consulting services. William Larkins, PhD, former vice president and general manager of Bedford Laboratories, will serve as chief executive officer of Custopharm.
Custopharm is Water Street's sixth investment in the pharmaceutical sector in the past six years. In 2013, Water Street partnered created the drug- development company, Celerity Pharmaceuticals. It also invested in Temptime Corporation, which specializes in time-temperature indicators for medical products. Last year, the firm merged BioClinica, Inc. and CCBR-SYNARC to create a provider of specialty outsourced clinical trial services. Water Street also owned AAIPharma Services, Inc., now part of Cambridge Major Laboratories Inc., and OraPharma, Inc., which was acquired by Valeant Pharmaceuticals in 2012.
Water Street targets investments ranging from $50 million to $500 million in four healthcare sectors: specialty distribution, medical and diagnostic products, health care services, and pharmaceutical products and services. .
Source: Water Street Healthcare Partners